Therapeutic antibodies represent an innovative class of drugs used to treat a wide range of diseases such as rheumatoid arthritis and cancer. Protein A chromatography resin is widely used in the production of therapeutic antibodies due to its high affinity and excellent selectivity for antibodies. Utilizing our expertise in protein design and genetic engineering, we have made significant improvements to ‘Wild type’ or “Native’ Protein A ligand. Immobilization of our improved Protein A ligand to highly cross-linked cellulose beads allows KANEKA KanCapA to exhibit alkaline resistance, stability over repeated cycle use, and to be used at high flow rates from laboratory to industrial scale with high binding capacity. KanCapA exhibits excellent process development options, narrow pH elution for all monoclonal antibodies and non-binding Fab properties. Mild pH elution avoids the formation of product aggregates. Data presented here compares Kaneka KanCapA with already marketed PA resins and demonstrate the extremely high potential of KanCapA as the new PA , mAb purification platform.